HCV Drugs in Development (Archived)

Drug Class	Sponsor and/or Company	Drug Name	Alt Name	Drug Status	Notes	AIDS#
A3 Adenosine receptor Agonist	Can-Fite BioPharma	CF102	CI-IB-MECA	Phase 1/2	Completed
Antihistamine		Chlorcyclizine		Phase 1	Recruiting	033660
Caspase Inhibitor	Gilead Sciences	GS-9450		Phase 2	Completed
Caspase Inhibitor	Conatus Pharmaceuticals Inc; Pfizer	PF-03491390	IDN-6556	Phase 2	Completed
Cyclophilin B Inhibitor	Novartis Pharmaceuticals	NIM-811	[Me-Ile-4] Cyclosporin A; SDZ-811	Phase 2	Completed	006796
Cyclophilin B Inhibitor	Aventis; Scynexis	SCY-635		Phase 2	Completed	189067
Cyclophilin D Inhibitor	Novartis Pharmaceuticals	Alisporivir	Debio-025; DEB025	Phase 3	Terminated	268533
DGAT1 inhibitor	Novartis Pharmaceuticals	LCQ-908	LCQ-908-ABA.002	Phase 2	Terminated
E2 glycoprotein MAb	Mass Biologics	MBL-HCV1		Phase 2	Ongoing, Not Recruiting
HCV Entry Inhibitor	ItherX	ITX-5061		Phase 1	Completed
HCV Nucleoside Inhibitor	Hoffmann-La Roche	RO-5428029		Phase 1	Completed
HCV Polymerase Inhibitor	Idenix Pharmaceuticals	IDX 21459		Phase 1	Terminated
HCV Polymerase Inhibitor	Idenix Pharmaceuticals	IDX-184		Phase 2	Completed	556345
HCV Polymerase Inhibitor	Vertex Pharmaceuticals Incorporated	Lomibuvir	VX-222; VCH-222	Phase 2	Completed	543506
HCV Polymerase Inhibitor	Gilead Sciences	GS-9669		Phase 2	Completed	543505
HCV Polymerase Inhibitor	Gilead Sciences	GS 6620		Phase 1	Completed	558193
HCV Polymerase Inhibitor	Pfizer	Filibuvir	PF-00868554	Phase 2	Completed	490021
HCV Polymerase Inhibitor	Boehringer Ingelheim Pharmaceuticals	Deleobuvir	BI-207127	Phase 3	Completed
HCV Polymerase Inhibitor	Abbott (AbbVie)	Dasabuvir	ABT-333	Phase 3	Recruiting
HCV Polymerase Inhibitor	Boehringer Ingelheim Pharmaceuticals	BILB 1941		Phase 1/2	Completed
HCV Polymerase Inhibitor	Roche	Balapiravir	R-1626; RO-4588161	Phase 2	Completed
HCV Polymerase Inhibitor	Alios	ALS-2200	VX-135	Phase 2	Completed
HCV Polymerase Inhibitor	Alios BioPharma	AL-335		Phase 1	Recruiting
HCV Polymerase Inhibitor	Achillion	ACH-3102		Phase 2	Completed	565907
HCV Polymerase Inhibitor	Abbott (AbbVie)	ABT-072		Phase 2	Completed
HCV Polymerase Inhibitor	Pharmasset/Roche	Mericitabine	RG-7128; RO-5024048	Phase 2	Completed	550380
HCV Polymerase Inhibitor	Idenix Pharmaceuticals	Valopicitabine	NM-283	Phase 2	Completed	418137
HCV Polymerase Inhibitor	Medivir; Tibotec Pharmaceuticals	TMC-649128		Phase 1	Terminated
HCV Polymerase Inhibitor	Gilead Sciences	Tegobuvir	GS-9190; GS-333126	Phase 2	Completed	485775
HCV Polymerase Inhibitor	Theravance Biopharma	TD-6450	TF-6450	Phase 1	Completed
HCV Polymerase Inhibitor	Hoffmann-La Roche	Setrobuvir	ANA-598	Phase 2	Completed	497335
HCV Polymerase Inhibitor	Viropharma; Pfizer; Gilead Sciences	Nesbuvir	HCV-796	Phase 2	Completed	376743
HCV Polymerase Inhibitor	Merck	MK-8408		Phase 2	Recruiting
HCV Polymerase Inhibitor	Merck	MK-3281		Phase 1	Terminated	510563
HCV Protease Inhibitor	Abbott (AbbVie)	ABT-450		Phase 3	Recruiting
HCV Protease Inhibitor	Abbott (AbbVie)	ABT-493		Phase 2	Recruiting
HCV Protease Inhibitor	Bristol-Myers Squibb	Asunaprevir	BMS-650032	Phase 3	Ongoing, Not Recruiting	501741
HCV Protease Inhibitor	Bristol-Myers Squibb	Beclabuvir	BMS-791325	Phase 3	Ongoing, Not Recruiting	493957
HCV Protease Inhibitor	Boehringer Ingelheim Pharmaceuticals	Ciluprevir	BILN 2061	Phase 2	Completed	195599
HCV Protease Inhibitor	Intermune; Roche	Danoprevir	RG-7227; ITMN-191	Phase 2	Completed	488730
HCV Protease Inhibitor	Boehringer Ingelheim Pharmaceuticals	Faldaprevir	BI-201335	Phase 3	Completed	506842
HCV Protease Inhibitor	TaiGen Biotechnology	Furaprevir	TG-2349	Phase 2	Not Yet Recruiting
HCV Protease Inhibitor	Vertex Pharmaceuticals Incorporated	VX-985		Phase 1	Completed
HCV Protease Inhibitor	Gilead Sciences	Vedroprevir	GS-9451	Phase 2	Completed	551450
HCV Protease Inhibitor	Merck	Vanihep™(Japan)	Vaniprevir; MK-7009	Phase 3	Completed	496721
HCV Protease Inhibitor	Presido	Ravidasvir	PPI-668	Phase 2/3	Recruiting	565898
HCV Protease Inhibitor	Schering-Plough	Narlaprevir	SCH-900518	Phase 2	Completed	501790
HCV Protease Inhibitor	Rottapharm Madaus	Legalon™	Sil; SHS; Silibinin sodium hemisuccinate	Phase 2/3	Terminated	513548
HCV Protease Inhibitor	Idenix Pharmaceuticals	IDX-320		Phase 1/2	Completed
HCV Protease Inhibitor	Gilead Sciences	GS-9256		Phase 2b	Completed
HCV Protease Inhibitor	Merck	Grazoprevir	MK-5172	Phase 3	Recruiting	501731
HCV Replication Inhibitor	Achillion	Sovaprevir	ACH-0141625; ACH-1625; Prodrug of ACH-1095	Phase 2	Completed	491583
HCV Replication Inhibitor	Valeant Pharmaceuticals; Kadmon Pharmaceuticals	Taribavirin	Viramidine; Ribamidine; ICN-3142	Phase 3	Completed	000198
HCV Replication Inhibitor	Novartis Pharmaceuticals	Zalbin™	Albinterferon; Albuferon; alb-IFN	Phase 2	Completed	184128
HCV Replication Inhibitor	Abbott (AbbVie)	ABT-530		Phase 2	Active, Not Recruiting
HCV Replication Inhibitor	Romark	Alinia™	Nitazoxanide; Xerovirin-C	Phase 2/3	Completed	057131
HCV Replication Inhibitor	Arrow Theraputics	AZD-7295		Phase 2	Completed	506699
HCV Replication Inhibitor	Bristol-Myers Squibb	BMS-824393		Phase 2a	Withdrawn
HCV Replication Inhibitor	ZymoGenetics; Bristol-Myers Squibb	BMS-914143; PEG-rIL-29	(man-made IL-29); PEG_IFN_lambda; BMS-914143	Phase 3	Completed
HCV Replication Inhibitor	Eiger BioPharmaceuticals	Clemizole		Phase 1b	Completed	033090
HCV Replication Inhibitor	Bristol-Myers Squibb	Daclatasvir	BMS-790052	NDA	2015	503558
HCV Replication Inhibitor	Novartis Pharmaceuticals	EDP-239		Phase 1	Active, Not Recruiting
HCV Replication Inhibitor	Merck	Elbasvir	MK-8742	Phase 2/3	Recruiting
HCV Replication Inhibitor	Gilead Sciences	GS-5816		Phase 2	Not Yet Recruiting
HCV Replication Inhibitor	Gilead Sciences	GS-9857		Phase 2	Recruiting
HCV Replication Inhibitor	GlaxoSmithKline	GSK2336805	JNJ56914845	Phase 2a	Completed	563249
HCV Replication Inhibitor	Gilead Sciences	Ledipasvir	GS-5885	Phase 3	Recruiting	557593
HCV Replication Inhibitor	Abbott (AbbVie)	Ombitasvir	ABT-267	Phase 3	Recruiting	541999
HCV Replication Inhibitor	Presidio Pharmaceuticals; Ascletis	PPI-461		Phase 1b	Completed	501737
HCV Replication Inhibitor	Idenix Pharmaceuticals	Samatasvir	IDX-719; IDX-380; MK-1894	Phase 1/2	Completed	564114
Immunomodulator	Biocad	Algeron	Cepeginterferon alfa 2b	Phase 3	Recruiting
Immunomodulator	Anadys Pharmaceuticals	ANA-773	RO-6864018	Phase 1	Completed
Immunomodulator	Cytheris SA	CYT107	Glyco-r-hIL-7; Interleukin-7	Phase 1/2a	Completed	398475
Immunomodulator	Idera Pharmaceuticals, Inc.	IMO-2125		Phase 1	Completed
Immunomodulator	Dynavax Technologies Corporation	SD101		Phase 1	Completed
Immunomodulator and Anti-inflammatory	Novelos Therapeutics; Cellectar Biosciences	NOV-205	BAM-205 (Glutathione and Inosine); Molixan	Phase 2	Completed
Interferon alpha 2b agonist	Biolex Therapeutics	Locteron™	Controlled Release Interferon alpha 2a	Phase 3	Not Yet Recruiting	001582
MMP inhibitor/Anti-fibrogenic	Conatus Pharmaceuticals Inc.	CTS-1027		Phase 2	Completed
MicroRNA Inhibitor	Santaris Pharma	Miravirsen	Anti-miR-122; SPC-3649	Phase 2	Ongoing, Not Recruiting
Natural Product	PhytoHealth Corporation	PHN-121		Phase 1/2	Terminated
Not Specified	Novartis Pharmaceuticals	BZF-961		Phase 1/2	Completed
PD-1 receptor MAb	Bristol-Myers Squibb	Nivolumab	MDX-1106; BMS-936558; ONO-4538	Phase 1	Completed
Stimulates T-helper cells	SciClone Pharmaceuticals	Golotimod	SCV-07; (gamma-glutamyl-L-tryptophan)	Phase 2	Completed	346667
Unknown	Merck	MK-1075		Phase 1	Not Yet Recruiting
Unknown	Merck	MK-2248		Phase 1	Completed
Unknown	Merck	MK-7680		Phase 1	Recruiting
Virucidal/Anti-phosphotidylserine	Peregrine Pharmaceuticals	Tarvacin™	Bavituximab	Phase 1/2	Completed
toll-like receptor-7 agonist	Gilead Sciences	GS-9620		Phase 1	Completed

Some useful sites where additional information on these drugs may be found:

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source. Database last updated: September 2024

Division of AIDS Anti-HIV/OI/TB Therapeutics Database

HCV Drugs in Development (Archived)